PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis.
Wang Z, Li R, Hou N, Zhang J, Wang T, Fan P, Ji C, Zhang B, Liu L, Wang Y, Kong J, Yao Q, Duan J, Zhao G, Ling R, Zhang J.
Wang Z, et al. Among authors: kong j.
J Immunother Cancer. 2023 Jun;11(6):e006890. doi: 10.1136/jitc-2023-006890.
J Immunother Cancer. 2023.
PMID: 37380368
Free PMC article.